Clinical trials: Hepatitis C Genotype 1
Hepatitis C
Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs
The investigator's hypothesis is that active injectors will show a partial reduction in markers of immune activation with HCV therapy whereas non-injectors will show a more significant reduction in these markers, and will exhibit…
- Trial name
- NCT02347345
- Testing
- Harvoni (Fixed dose combination ledipasvir/sofosbuvir)
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Rockefeller University